GSK plc receives US approval for Jemperli and reports positive R&D update: Can GSK regain momentum?

Traders Union
All News
Stocks
GSK slips 0.05% today to GBX1,873

Highlights

GSK received US accelerated approval for Jemperli in a subset of rectal cancer, immediately increasing its reach in the US oncology market.
GSK reported positive early-stage data for its Ris-Rez therapy in small cell lung cancer, expanding the oncology pipeline and future growth prospects.
Shares of GSK are trading in a short- to medium-term uptrend with strong buyer activity, projected to move within the GBX1,855 to GBX1,890 range over several days.

Regulatory milestones and trial results drive expanding US oncology strategy

GSK received US accelerated approval for its oncology drug Jemperli for a select group of rectal cancer patients, a development that immediately expands the company’s commercial presence in the US oncology market, according to Kalkinemedia. This regulatory milestone enables GSK to access additional patient populations and may provide new revenue streams from the therapy’s introduction. Alongside this, GSK reported positive early-stage data for its Ris-Rez therapy in small cell lung cancer, which broadens its R&D pipeline and adds to the long-term growth narrative for its oncology business.

Mixed momentum signals as price hovers between key technical levels

On the technical front, GSK is trading above its MA-20 and MA-50 on the H1 chart, while remaining below the long-term MA-200 at GBX1,951. The Ichimoku Kijun line at GBX1,867 serves as immediate support. Momentum indicators present a mixed picture: MACD and ADX are supportive of further gains, while RSI is moderately bullish. Stoch RSI currently signals an oversold condition, CCI holds neutral, and Bull/Bear Power shows buyer dominance intraday. The Awesome Oscillator does not confirm the prevailing trend.

Sideways scenario dominates as rangebound trading contains near-term outlook

In the short term, GSK is expected to remain within a trading range of GBX1,855 to GBX1,890 over the coming sessions, consistent with typical volatility at current levels. The probability of an upward move is estimated at 67%, while downside risk accounts for 33%. The base case calls for sideways price action, but a move above GBX1,890 would signal renewed bullish momentum, whereas loss of support at GBX1,855 may open the path for further declines.

Viktoras Karapetjanc, expert at Traders Union, sees GSK’s recent US accelerated approval for Jemperli as a firm validation of its oncology pipeline and a catalyst for further market expansion. He believes the early positive clinical data and dominant buyer sentiment support a moderately bullish outlook in the near term. Strong fundamentals back the current price structure above key short- and medium-term averages. Tactical moves will hinge on price action around the GBX1,855 and GBX1,890 levels. "If GSK can sustain its momentum above support, I expect a constructive bias to prevail as fundamentals and sentiment align."

Earlier, analysts noted that GSK stock was consolidating within a defined range, supported by mixed technical momentum and recent regulatory developments. The current article adds new regulatory approvals and positive R&D updates to the outlook, highlighting GBX1,890 as a key level to watch for any renewed upside momentum.

Source of Data: GSK Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.